MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 08-06-2025
Country |
 Britain |
IPO year |
2017 |
Industry |
Biotechnology |
Stock Exchange |
NASDAQ GLOBAL |
Shares |
652 M |
Market Cap[1] |
$ 69.7 B |
EBITDA (LTM) |
$ -73.6 M |
P/E (LTM) |
- |
P/S (LTM) |
309.92 |
EPS (LTM) |
-0.18 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
- | 2.43 % | $ 254 M | Nasdaq Global Select Market |  Germany |
 |
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market |  USA |
 |
Adverum Biotechnologies
ADVM
|
- | - | $ 86.2 M | Nasdaq Global Market | USA |
 |
AlloVir
ALVR
|
- | 4.14 % | $ 49.1 M | Nasdaq Global Select Market | USA |
 |
Amgen
AMGN
|
$ 340.0 | -0.75 % | $ 183 B | Nasdaq Global Select Market,SPB | USA |
 |
Amneal Pharmaceuticals
AMRX
|
$ 12.32 | -0.24 % | $ 3.86 B | NYSE | USA |
 |
Applied Molecular Transport
AMTI
|
- | - | $ 10.1 M | Nasdaq Global Select Market,SPB | USA |
 |
Applied Therapeutics
APLT
|
- | - | $ 8.42 M | Nasdaq Global Market,SPB | USA |
 |
I-Mab
IMAB
|
- | - | $ 866 M | Nasdaq Global Select Market |  China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
- | - | $ 40.3 B | Nasdaq Global Select Market | USA |
 |
Genfit SA
GNFT
|
- | 2.54 % | $ 160 B | Nasdaq Global Select Market |  France |
 |
Arcutis Biotherapeutics
ARQT
|
$ 23.27 | -1.63 % | $ 2.96 B | Nasdaq Global Select Market,SPB | USA |
 |
Biophytis SA
BPTS
|
- | -13.47 % | $ 169 M | Nasdaq Capital Market | France |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.36 | -2.16 % | $ 362 M | Nasdaq Global Select Market | Britain |
 |
AVROBIO
AVRO
|
- | 1083.1 % | $ 745 M | Nasdaq Global Select Market | USA |
 |
Ayala Pharmaceuticals
AYLA
|
- | - | $ 7.46 M | Nasdaq Global Market |  Israel |
 |
AstraZeneca PLC
AZN
|
- | - | $ 96.9 B | Nasdaq Global Select Market | Britain |
 |
Midatech Pharma plc
MTP
|
- | -18.52 % | $ 27.3 M | Nasdaq Global Select Market | Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
BeiGene, Ltd.
BGNE
|
- | 0.49 % | $ 251 B | Nasdaq Global Select Market |  Cayman-islands |
 |
Alterity Therapeutics Limited
ATHE
|
$ 3.76 | 4.35 % | $ 9.05 B | Nasdaq Capital Market |  Australia |
 |
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | USA |
 |
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | USA |
 |
Aytu BioScience
AYTU
|
$ 2.57 | -3.38 % | $ 16.1 M | Nasdaq Capital Market | USA |
 |
Avid Bioservices
CDMO
|
- | - | $ 789 M | Nasdaq Capital Market | USA |
 |
Cidara Therapeutics
CDTX
|
- | - | $ 1.41 B | Nasdaq Global Market | USA |
 |
Институт стволовых клеток человека
ISKJ
|
- | - | - | MOEX |  Russia |
 |
Checkpoint Therapeutics
CKPT
|
- | - | $ 169 M | Nasdaq Capital Market | USA |
 |
Cellectar Biosciences
CLRB
|
$ 2.75 | 1.48 % | $ 7.17 M | Nasdaq Capital Market | USA |
 |
Aeterna Zentaris
AEZS
|
- | 5.93 % | $ 314 M | Nasdaq Capital Market |  Canada |
 |
Checkmate Pharmaceuticals
CMPI
|
- | - | $ 231 M | Nasdaq Global Market | USA |
 |
AgeX Therapeutics
AGE
|
- | -10.17 % | $ 12.2 K | NYSE American | USA |
 |
Concert Pharmaceuticals
CNCE
|
- | - | $ 401 M | Nasdaq Global Market | USA |
 |
Aeglea BioTherapeutics
AGLE
|
- | - | $ 1.01 B | Nasdaq Global Market | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
- | - | $ 26.5 M | Nasdaq Global Select Market | USA |
 |
CTI BioPharma Corp.
CTIC
|
- | - | $ 1.2 B | Nasdaq Capital Market | USA |
 |
AIkido Pharma
AIKI
|
- | 1.93 % | $ 17.4 M | Nasdaq Capital Market | USA |
 |
Aptose Biosciences
APTO
|
- | -45.71 % | $ 1.2 M | Nasdaq Capital Market | Canada |
 |
Cyclacel Pharmaceuticals
CYCCP
|
- | -4.36 % | $ 27 M | Nasdaq Capital Market | USA |
 |
Cyclerion Therapeutics
CYCN
|
$ 3.48 | -16.14 % | $ 8.76 M | Nasdaq Global Select Market | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
- | - | $ 2.18 B | Nasdaq Global Select Market,SPB | USA |
 |
Akero Therapeutics
AKRO
|
- | - | $ 3.67 B | Nasdaq Global Select Market,SPB | USA |
 |
Dynavax Technologies Corporation
DVAX
|
- | - | $ 2.02 B | Nasdaq Capital Market | USA |
 |
CureVac N.V.
CVAC
|
- | - | $ 867 M | Nasdaq Global Market | Germany |
 |
Dyadic International
DYAI
|
$ 0.88 | 1.66 % | $ 31.8 M | Nasdaq Capital Market | USA |
 |
BioNTech SE
BNTX
|
$ 89.62 | -1.82 % | $ 27.2 B | Nasdaq Global Select Market | Germany |
 |
Coherus BioSciences
CHRS
|
$ 1.67 | - | $ 196 M | Nasdaq Global Market | USA |
 |
Akari Therapeutics, Plc
AKTX
|
$ 3.8 | 7.34 % | $ 256 B | Nasdaq Capital Market | Britain |
 |
Akouos
AKUS
|
- | 0.23 % | $ 488 M | Nasdaq Global Select Market | USA |
 |
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB | USA |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.